Chinese Rare Disease-Focused Biotech Startup Citrine Medicine Raises US$80M Series A

Citrine Medicine aims to develop an ecosystem for rare disease patients in China

Citrine Medicine, a Chinese rare disease-focused therapeutics startup founded by Eight Roads, F-Prime Capital, and Vivo Capital, has raised $80 million in a Series A funding round, according to a press release on Monday.

The latest financing round was led by Quan Capital, a medical and healthcare-focused venture capital firm, while new investors 3H Health Investment and WU Capital also participated in the round along with the three founding backers.

The startup, which imports rare disease medicines to China, aims to deliver these drugs to the Chinese market and develop the first ever rare disease ecosystem in the country, with the prospect of helping tens of millions of patients, according to the press release.

With 20 million people suffering from rare diseases in Mainland China, and none eligible for free treatment, the market holds untapped potential for Citrine as the current treatment options are unaffordable for the majority of patients in need. Moreover, these diseases are often difficult to diagnose, difficult to treat, and difficult to guarantee recovery, according to the press report.

Since its inception in 2019, Citrine has assembled a best-in-class team of veterans with decades of work experience in rare diseases and the healthcare market in China, according to the press report.

Rebecca Lin, Partner of Eight Roads and a director of Citrine’s Board, said, “Citrine is dedicated to bringing in safe and effective medications to patients in China suffering from rare diseases. Our aspiration is to build an ecosystem of support for the patients, working together with various stakeholders to fundamentally remove the accessibility and affordability obstacles.”

Recent reforms in regulation and policy in China have expedited the drug approval process for rare disease drugs. These new regulations allow rare-disease drugs, also called orphan drugs, to be submitted for approval in China with only overseas clinical trial data.

According to the statement, Citrine will focus on validated or approved medications, while at the same time helping products speed up their development processes globally.

“Citrine is a unique platform which can leverage the resources of all investors and benefits from the synergy of this extensive network, including Eight Roads’ global resources and connections. We believe Citrine is well-positioned to build something meaningful for the rare disease community,” Lin added.

F-Prime’s Principal, Dr. Chong Xu said, “F-Prime Capital is a strong believer and long-time investor in companies developing drugs for orphan disease patients in need. We helped found Citrine because we were excited about the potential for the company to significantly improve the lives of patients and families in China affected by rare diseases.”

Dr. Wu Hui, Managing Director of Quan Capital, said, “We look forward to providing strong support for Citrine’s capabilities and pipelines in terms of talent recruitment, local operating resources, and overseas product cooperation. With the strong support of investors, we are confident that Citrine will become a leader in this field and accelerate the development of innovative rare disease drugs in China and globally.”

Header image by Volodymyr Hryshchenko on Unsplash

SHARE THIS STORY

Share on facebook
Share on twitter
Share on linkedin
Share on email

RELATED POSTS

What Should Employees Do in a Crisis

What Should Employees Do in a Crisis?

At the start of January 2023, a drunk man in an Air India flight’s business class urinated over a 72-year-old woman sitting beside him. The man, Shankar Mishra, was the Vice President of the financial services company Wells Fargo (he was fired following the incident). In itself, the incident is disgusting.

Top 5 AI Companies in the World

Top 5 AI Companies in the World

Technological developments are driven by the human need to make life easier and complete tasks faster and more efficiently. The drastic growth of technology in recent years has paved the way for artificial intelligence (AI) to become an integral part of almost every industry—from education and lifestyle to music and sports. It is everywhere. And by the looks of it, it is here to stay.

3 High Demand Metaverse Jobs in Future That Your Kids Should Look into

3 High Demand Metaverse Jobs in Future That Your Kids Should Look into

It’s no wonder why Jumpstart Media named “metaverse” one of the top emerging trends and technologies to look forward to in 2023. With an expected compound annual growth rate (CAGR) of 39.4% from 2022 to 2030, Grand View Research forecasts that the global metaverse market is set to expand exponentially. From fashion shows, gaming, luxury products, sports and travel to art, many industries are tapping into the metaverse’s potential.

4 Most Anticipated Tech IPOs of 2023

4 Most Anticipated Tech IPOs of 2023

The technology industry has been a driving force in shaping the global economy for decades and the initial public offerings (IPOs) of technology companies are often highly-anticipated events. In 2022, the tech IPO market saw a slowdown compared to the previous year, 2021.

5-Luxury-Items-That-Are-Worth-the-Investment

5 Luxury Items That Are Worth the Investment

The world of luxury items is one of elegance and exclusivity, with their value increasing as time passes. They are unattainable and highly coveted by the masses. Plus, luxury products have a Veblen effect on the market—as their price rises, their demand does, too.

How Do You Know When to Give Up on Your Startup?

How Do You Know When to Give Up on Your Startup?

Starting a new business is never an easy task. You put your heart into it and spend countless hours working on what you believe will make someone happy or solve society’s problems. But sometimes, startups don’t work out as planned—this can be both disheartening and discouraging.